Warhead envy: why AstraZeneca needed Spirogen
This article was originally published in Scrip
Executive Summary
AstraZeneca's MedImmune has strengthened one of the two key pillars of its oncology platform with the acquisition of Spirogen. The deal, which sees it paying $200m up front and up to $220m linked to future milestones, brings it a potent cytotoxic agent for use in antibody-drug conjugate (ADC) development (scripintelligence.com, 15 October 2013).